NCT04007835View on ClinicalTrials.gov

Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI

NAUnknownINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

July 31, 2019

Primary Completion Date

July 31, 2021

Study Completion Date

December 31, 2021

Conditions
NSCLC
Interventions
DRUG

Anlotinib Hydrochloride

anlotinib (12 mg orally daily for 14 days every 21 days cycle) combined with one of EGFR-TKIs

Trial Locations (1)

510080

Guangdong General Hospital, Guangzhou

Sponsors
All Listed Sponsors
collaborator

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY

lead

Guangdong Association of Clinical Trials

OTHER